Inovio begins testing new HIV vaccine

Inovio Pharmaceuticals has announced that it began the testing of a new vaccine for use against HIV on September 20.

Pennavax-B is a DNA vaccine that uses a proprietary electroporation technique developed by Inovio. Electroporation uses millisecond long electrical pulses to help the DNA vaccine to permeate cell membranes, according to the Philadelphia Business Journal. This technique allows for a significantly greater uptake of the biological material that was injected into local tissue.